Synonyms:
AZD2014;
AZD2014;
3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide;
CHEMBL2336325;
3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide;
C25H30N6O3;
3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide;
3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide;
Benzamide, 3-(2,4-bis((3S)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-N-methyl-;
Vistusertib [INN];
Benzamide, 3-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-N-methyl-;
Vistusertib [USAN];
1009298-59-2;
Vistusertib (JAN/INN);
MLS006011011;
SCHEMBL290672;
GTPL7699;
AOB3574;
DTXSID20143584;
EX-A155;
SYN1167;
BCP05748;
KS-000000YA;
Vistusertib;
BDBM50429701;
MFCD22628784;
s2783;
ZINC59258964;
AKOS024464879;
BCP9000362;
CS-0701;
DB11925;
QC-4554;
SB16565;
AZD-2014;
NCGC00346698-11;
4CA-0223;
AC-28425;
AS-16302;
BC600520;
HY-15247;
SC-62590;
SMR004702809;
AB0095803;
SW219704-1;
AZD 2014;
X3569;
D10887;
W-5962;
J-000268;
3-[2,4-Bis-[(3S)-3-methyl-4-morpholinyl]-pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide;
D0Z2UQ;
A8373;
Vistusertib, 98%, a novel mTOR inhibitor - 100MG 100mg;
UNII-0BSC3P4H5X;
vistusertib (AZD2014);
0BSC3P4H5X;
cc-551;
Keywords: 1009298-59-2,MFCD22628784,1P0003OQ,Benzamide, 3-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-N-methyl-,C25H30N6O3
Inquire